Alliance Pharma exec offloads 300,000 shares
20th Jan 2014 15:49
Speciality drugs firm Alliance Pharma announced Monday that Executive Director Anthony Booley's share in the company was reduced by 300,000 shares after his wife Lynette sold a portion of her stake. Booley, who joined the company in 1998, and his wife earned £100,500 from the sale after disposing
Read moreTuesday broker round-up UPDATE
17th Dec 2013 08:14
Advanced Medical Solutions: Panmure Gordon downgrades from buy to hold with a target price of 102p. Antofagasta: Canaccord Genuity cuts target price from 1110p to 1035p, while staying with its buy recommendation. ASOS: Panmure Gordon increases target price from 5950p to 6126p, while downgrading fr
Read moreThursday broker round-up UPDATE
14th Nov 2013 09:21
Afren: Goldman Sachs moves target price from 260p to 270p and retains its strong buy recommendation. APR Energy: Citi raises target price from 1250p to 1350p reiterating a buy recommendation. Atkins: Investec places both its target price (prev.: 1025p) and its reduce rating under review. Babcock
Read moreTuesday broker round-up UPDATE
5th Nov 2013 08:57
Afren: FinnCap ups target price from 130p to 140p keeping a hold recommendation. African Barrick Gold: Westhouse Securities raises target price from 115p to 170p, while downgrading to sell. Associated British Foods: Numis downgrades to reduce with a target price of 1845p. Panmure Gordon ups target
Read moreThursday broker round-up UPDATE
19th Sep 2013 08:20
ASOS: Canaccord Genuity increases target price from 3400p to 6200p and upgrades to buy. Associated British Foods: Jefferies raises target price from 1650p to 1750p and retains a hold recommendation. Barclays: Alphavalue upgrades from add to buy with a target price of 344.20p. BHP Billiton: Nomura
Read moreTuesday broker round-up UPDATE
2nd Apr 2013 08:28
Afren: Liberum Capital shifts target price from 123p to 130p maintaining a hold recommendation. Amara Mining: Numis initiates with a target price of 80p and a buy recommendation. APR Energy: Espirito Santo downgrades to sell with a target price of 680p. ASOS: Goldman Sachs increases target price
Read moreFirst Derivatives strikes deal with Australian Securities and Investment Commission
13th Dec 2012 10:29
First Derivatives has signed a multi-year annual software licence with the Australian Securities and Investment Commission to provide a new market surveillance system, the company reported Thursday. The Irish-based provider of software and consulting services will implement its Delta Stream, a mark
Read moreRandgold Resources CEO sells three million quid's worth of shares
14th Nov 2012 16:30
- Please note: This is a revised version of a story which previously contained information that was incorrect. After what has been a less-than-impressive year, the Chief Executive of FTSE 100 gold miner Randgold Resources, Mark Bristow, sold more than three million pounds worth of shares. Bristo
Read moreDiageo Chief sells 50,000 shares
13th Nov 2012 17:04
Diageo's Chief Executive Officer, Paul Walsh, sliced a chunk off his stake in the drinks giant with the sale of 50,000 shares on Monday. The transaction follows the company's purchase of a stake in Indian spirits group United Spirits Limited (USL). Diageo said on Friday that it is to acquire a 27
Read moreThursday broker round-up - UPDATE
18th Oct 2012 09:24
Ashtead: UBS raises target from 375p to 400p, buy rating kept. ASOS: Panmure Gordon keeps buy rating and 2,530p target. AZ Electronic Materials: Goldman Sachs upgrades to conviction buy. Booker: Panmure Gordon keeps buy rating and 108p target. Britvic: Panmure Gordon keeps hold rating and 380p t
Read moreTuesday broker round-up
2nd Oct 2012 08:17
African Barrick Gold: Deutsche Bank raises target from 510p to 540p, hold rating kept. African Minerals: Deutsche Bank cuts target from 708p to 610p, buy rating kept. Allocate Software: N+1 Brewin downgrades to hold, target cut from 94p to 80p. Babcock: Investec raises target from 970p to 100p, b
Read moreFirst Derivatives profits up but expects tough year ahead
28th May 2012 09:35
Capital markets software and consultancy provider, First Derivatives, has seen a big jump in pre-tax profits but warns regulation could make life difficult in the years ahead. Total revenues for the 12 months to the end of March were £46.1m, up 25.4% on the prior year. Normalised pre-tax profits (a
Read moreUPDATE: Tuesday broker round-up
18th Oct 2011 09:21
BP: UBS raises target from 450p to 480p, keeps buy rating. Whitbread: Peel Hunt keeps buy stance and 2,096p target. Whitbread: Evolution Securities confirms buy recommendation and 1,750p target. F&C Asset Management: Singer Capital Markets cuts target from 70p to 65p, fair value rating kept. Be
Read moreFirst Derivatives non-exec pockets £550,000
7th Jul 2011 15:17
First Derivatives non-executive director Michael O' Neill has pocketed £550,000 from the sale of shares in the Northern Irish provider of software services to investment banks and hedge funds. He sold 100,000 at 550p a time, but still has 640,000 shares, or nearly 4% of the company. "The shares we
Read moreFirst Derivatives on a roll
25th May 2011 09:18
First Derivatives, which supplies software and consulting services to banks and hedge funds, posted higher profits in the year to 28 February as the company continues developing new products and winning clients. Pre-tax profits were up by 15% from the previous year at £6.5m, on revenues that soared
Read more